Advertisement

The Use of the Biomarker Procalcitonin in Pediatric Cardiovascular Disorders

  • Raj SahuleeEmail author
  • Jaclyn McKinstry
  • Sujata B. Chakravarti
Intensive Care Medicine (E Cheung and T Connors, Section Editors)
  • 3 Downloads
Part of the following topical collections:
  1. Topical Collection on Intensive Care Medicine

Abstract

Purpose of Review

We highlight the recent data investigating the use of the biomarker procalcitonin (PCT) in several clinical scenarios involving children with cardiovascular disorders. The diagnostic, therapeutic, and prognostic uses of PCT are discussed.

Recent Findings

Limited pediatric-specific data, but substantial adult studies have described the use of PCT in 4 clinical scenarios: infection after cardiac surgery, heart failure and respiratory illness, infective endocarditis, and cardiac arrest.

Summary

Procalcitonin is a biomarker with increasing utility in pediatric cardiovascular illness. Procalcitonin has successfully been shown useful in detecting bacterial infection after cardiac surgery, differentiating heart failure from respiratory infections, aiding the rapid diagnosis of infective endocarditis, and prognosticating patient outcomes after cardiac arrest. It also seems to perform superiorly to other inflammatory markers in these settings as well. A better understanding of the utility of PCT monitoring could help clinicians make more rapid and accurate clinical decisions.

Keywords

Procalcitonin Biomarker Cardiac surgery Heart failure Infective endocarditis Cardiac arrest 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Müller B, White JC, Nylén ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab. 2001;86(1):396–404.  https://doi.org/10.1210/jcem.86.1.7089.Google Scholar
  2. 2.
    Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000;181(1):176–80.  https://doi.org/10.1086/315214.CrossRefGoogle Scholar
  3. 3.
    Schuetz P, Aujesky D, Müller C, Müller B. Biomarker-guided personalised emergency medicine for all - hope for another hype? Swiss Med Wkly. 2015a;145:w14079.  https://doi.org/10.4414/smw.2015.14079.Google Scholar
  4. 4.
    Schuetz P, Christ-Crain M, Müller B. Procalcitonin and other biomarkers to improve assessment and antibiotic stewardship in infections--hope for hype? Swiss Med Wkly. 2009a;139(23–24):318–26.Google Scholar
  5. 5.
    Christ-Crain M, Müller B. Procalcitonin in bacterial infections--hype, hope, more or less? Swiss Med Wkly. 2005;135(31–32):451–60.Google Scholar
  6. 6.
    Christ-Crain M, Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur Respir J. 2007;30(3):556–73.  https://doi.org/10.1183/09031936.00166106.CrossRefGoogle Scholar
  7. 7.
    Linscheid P, Seboek D, Zulewski H, Keller U, Müller B. Autocrine/paracrine role of inflammation-mediated calcitonin gene-related peptide and adrenomedullin expression in human adipose tissue. Endocrinology. 2005;146(6):2699–708.  https://doi.org/10.1210/en.2004-1424.CrossRefGoogle Scholar
  8. 8.
    Becker KL, Snider R, Nylen ES. Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med. 2008;36(3):941–52.  https://doi.org/10.1097/CCM.0B013E318165BABB.CrossRefGoogle Scholar
  9. 9.
    Meisner M. Update on procalcitonin measurements. Ann Lab Med. 2014;34(4):263–73.  https://doi.org/10.3343/alm.2014.34.4.263.CrossRefGoogle Scholar
  10. 10.
    Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase-negative staphylococci. Infection. 2007;35(5):352–5.  https://doi.org/10.1007/s15010-007-7065-0.CrossRefGoogle Scholar
  11. 11.
    Müller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, Mueller B, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010;138(1):121–9.  https://doi.org/10.1378/chest.09-2920.CrossRefGoogle Scholar
  12. 12.
    van Nieuwkoop C, Bonten TN, van't Wout JW, Kuijper EJ, Groeneveld GH, Becker MJ, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care. 2010;14(6):R206.  https://doi.org/10.1186/cc9328.CrossRefGoogle Scholar
  13. 13.
    Müller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10.  https://doi.org/10.1186/1471-2334-7-10.CrossRefGoogle Scholar
  14. 14.
    Schuetz P, Christ-Crain M, Albrich W, Zimmerli W, Mueller B, Group, P. S. Guidance of antibiotic therapy with procalcitonin in lower respiratory tract infections: insights into the ProHOSP study. Virulence. 2010b;1(2):88–92.  https://doi.org/10.4161/viru.1.2.10488.CrossRefGoogle Scholar
  15. 15.
    Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011c;37(2):384–92.  https://doi.org/10.1183/09031936.00035610.CrossRefGoogle Scholar
  16. 16.
    Christ-Crain M, Stolz D, Bingisser R, Müller C, Miedinger D, Huber PR, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006;174(1):84–93.  https://doi.org/10.1164/rccm.200512-1922OC.CrossRefGoogle Scholar
  17. 17.
    Stockmann C, Ampofo K, Killpack J, Williams DJ, Edwards KM, Grijalva CG, et al. Procalcitonin accurately identifies hospitalized children with low risk of bacterial community-acquired pneumonia. J Pediatric Infect Dis Soc. 2018;7(1):46–53.  https://doi.org/10.1093/jpids/piw091.CrossRefGoogle Scholar
  18. 18.
    Matha SM, Rahiman SN, Gelbart BG, Duke TD. The utility of procalcitonin in the prediction of serious bacterial infection in a tertiary paediatric intensive care unit. Anaesth Intensive Care. 2016;44(5):607–14.CrossRefGoogle Scholar
  19. 19.
    Los Arcos M, Rey C, Concha A, Medina A, Prieto B. Acute-phase reactants after paediatric cardiac arrest. Procalcitonin as marker of immediate outcome. BMC Pediatr. 2008;8:18.  https://doi.org/10.1186/1471-2431-8-18.CrossRefGoogle Scholar
  20. 20.
    • Li X, Wang X, Li S, Yan J, Li D. Diagnostic value of procalcitonin on early postoperative infection after pediatric cardiac surgery. Pediatr Crit Care Med. 2017;18(5):420–8.  https://doi.org/10.1097/PCC.0000000000001118 Prospective study of 238 children undergoing cardiac surgery demonstrating association of PCT changes with bacterial infection, and PCT outperformance of WBC or CRP.CrossRefGoogle Scholar
  21. 21.
    Nahum E, Schiller O, Livni G, Bitan S, Ashkenazi S, Dagan O. Procalcitonin level as an aid for the diagnosis of bacterial infections following pediatric cardiac surgery. J Crit Care. 2012;27(2):220.e11–6.  https://doi.org/10.1016/j.jcrc.2011.07.076.CrossRefGoogle Scholar
  22. 22.
    Jaworski R, Haponiuk I, Irga-Jaworska N, Steffens M, Chojnicki M, Paczkowski K, et al. Monitoring both procalcitonin and C-reactive protein in the early period after tetralogy of Fallot correction in children promotes rational antibiotic use. Adv Med Sci. 2018;63(1):112–8.  https://doi.org/10.1016/j.advms.2017.10.003.CrossRefGoogle Scholar
  23. 23.
    Chakravarti SB, Reformina DA, Lee TM, Malhotra SP, Mosca RS, Bhatla P. Procalcitonin as a biomarker of bacterial infection in pediatric patients after congenital heart surgery. Ann Pediatr Cardiol. 2016;9(2):115–9.  https://doi.org/10.4103/0974-2069.180665.CrossRefGoogle Scholar
  24. 24.
    Celebi S, Koner O, Menda F, Balci H, Hatemi A, Korkut K, et al. Procalcitonin kinetics in pediatric patients with systemic inflammatory response after open heart surgery. Intensive Care Med. 2006;32(6):881–7.  https://doi.org/10.1007/s00134-006-0180-z.CrossRefGoogle Scholar
  25. 25.
    •• Zant R, Stocker C, Schlapbach LJ, Mayfield S, Karl T, Schibler A. Procalcitonin in the early course post pediatric cardiac surgery. Pediatr Crit Care Med. 2016;17(7):624–9.  https://doi.org/10.1097/PCC.0000000000000751 Prospective study of 221 children after cardiac surgery associated PCT with adverse events.CrossRefGoogle Scholar
  26. 26.
    Wuerz RC, Meador SA. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann Emerg Med. 1992;21(6):669–74.CrossRefGoogle Scholar
  27. 27.
    Maisel A, Neath SX, Landsberg J, Mueller C, Nowak RM, Peacock WF, et al. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (biomarkers in acute heart failure) trial. Eur J Heart Fail. 2012;14(3):278–86.  https://doi.org/10.1093/eurjhf/hfr177.CrossRefGoogle Scholar
  28. 28.
    Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847–54.  https://doi.org/10.1001/archinte.168.8.847.CrossRefGoogle Scholar
  29. 29.
    Alba GA, Truong QA, Gaggin HK, Gandhi PU, De Berardinis B, Magrini L, et al. Diagnostic and prognostic utility of procalcitonin in patients presenting to the emergency department with dyspnea. Am J Med. 2016;129(1):96–104.e7.  https://doi.org/10.1016/j.amjmed.2015.06.037.CrossRefGoogle Scholar
  30. 30.
    Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009b;302(10):1059–66.  https://doi.org/10.1001/jama.2009.1297.CrossRefGoogle Scholar
  31. 31.
    Schuetz P, Daniels LB, Kulkarni P, Anker SD, Mueller B. Procalcitonin: a new biomarker for the cardiologist. Int J Cardiol. 2016;223:390–7.  https://doi.org/10.1016/j.ijcard.2016.08.204.CrossRefGoogle Scholar
  32. 32.
    Wu G, Wu S, Wu H. Comparison of procalcitonin guidance-administered antibiotics with standard guidelines on antibiotic therapy in children with lower respiratory tract infections: a retrospective study in China. Med Princ Pract. 2017;26(4):316–20.  https://doi.org/10.1159/000477936.CrossRefGoogle Scholar
  33. 33.
    Baer G, Baumann P, Buettcher M, Heininger U, Berthet G, Schäfer J, et al. Procalcitonin guidance to reduce antibiotic treatment of lower respiratory tract infection in children and adolescents (ProPAED): a randomized controlled trial. PLoS One. 2013;8(8):e68419.  https://doi.org/10.1371/journal.pone.0068419.CrossRefGoogle Scholar
  34. 34.
    Hoshina T, Nanishi E, Kanno S, Nishio H, Kusuhara K, Hara T. The utility of biomarkers in differentiating bacterial from non-bacterial lower respiratory tract infection in hospitalized children: difference of the diagnostic performance between acute pneumonia and bronchitis. J Infect Chemother. 2014;20(10):616–20.  https://doi.org/10.1016/j.jiac.2014.06.003.CrossRefGoogle Scholar
  35. 35.
    Ochi F, Higaki T, Ohta M, Yamauchi T, Tezuka M, Chisaka T, et al. Procalcitonin as a marker of respiratory disorder in neonates. Pediatr Int. 2015;57(2):263–8.  https://doi.org/10.1111/ped.12505.CrossRefGoogle Scholar
  36. 36.
    Noori NM, Mahjoubifard M, Shahramian I, Teimouri A, Jahangirifard A. Comparison between procalcitonin, brain natriuretic peptide, and uric acid in children with cardiomyopathy and controls. Biomed Res Int. 2015;2015:510450.  https://doi.org/10.1155/2015/510450.CrossRefGoogle Scholar
  37. 37.
    Pierce D, Calkins BC, Thornton K. Infectious endocarditis: diagnosis and treatment. Am Fam Physician. 2012;85(10):981–6.Google Scholar
  38. 38.
    Rast AC, Kutz A, Felder S, Faessler L, Steiner D, Laukemann S, et al. Procalcitonin improves the Glasgow prognostic score for outcome prediction in emergency patients with cancer: a cohort study. Dis Markers. 2015b;2015:795801.  https://doi.org/10.1155/2015/795801.CrossRefGoogle Scholar
  39. 39.
    Rast AC, Knobel D, Faessler L, Kutz A, Felder S, Laukemann S, et al. Use of procalcitonin, C-reactive protein and white blood cell count to distinguish between lower limb erysipelas and deep vein thrombosis in the emergency department: a prospective observational study. J Dermatol. 2015a;42(8):778–85.  https://doi.org/10.1111/1346-8138.12922.CrossRefGoogle Scholar
  40. 40.
    Laukemann S, Kasper N, Kulkarni P, Steiner D, Rast AC, Kutz A, et al. Can we reduce negative blood cultures with clinical scores and blood markers? Results from an observational cohort study. Medicine (Baltimore). 2015;94(49):e2264.  https://doi.org/10.1097/MD.0000000000002264.CrossRefGoogle Scholar
  41. 41.
    Mueller C, Huber P, Laifer G, Mueller B, Perruchoud AP. Procalcitonin and the early diagnosis of infective endocarditis. Circulation. 2004;109(14):1707–10.  https://doi.org/10.1161/01.CIR.0000126281.52345.52.CrossRefGoogle Scholar
  42. 42.
    Cornelissen CG, Frechen DA, Schreiner K, Marx N, Krüger S. Inflammatory parameters and prediction of prognosis in infective endocarditis. BMC Infect Dis. 2013;13:272.  https://doi.org/10.1186/1471-2334-13-272.CrossRefGoogle Scholar
  43. 43.
    Apiwattanakul N, Wanitkun S, Chongtrakool P, Sirinavin S. A patient with penicillin-resistant viridans group streptococcal endocarditis and unusual reactions to vancomycin. Southeast Asian J Trop Med Public Health. 2008;39(6):1088–91.Google Scholar
  44. 44.
    Akyıldız B, Ülgen-Tekerek N, Özyurt A, Pamukçu Ö, Narin N. Cerebrovascular complication of infective endocarditis complicated with abdominal trauma. Turk J Pediatr. 2016;58(5):554–7.  https://doi.org/10.24953/turkjped.2016.05.017.CrossRefGoogle Scholar
  45. 45.
    Engel H, Ben Hamouda N, Portmann K, Delodder F, Suys T, Feihl F, et al. Serum procalcitonin as a marker of post-cardiac arrest syndrome and long-term neurological recovery, but not of early-onset infections, in comatose post-anoxic patients treated with therapeutic hypothermia. Resuscitation. 2013;84(6):776–81.  https://doi.org/10.1016/j.resuscitation.2013.01.029.CrossRefGoogle Scholar
  46. 46.
    Bro-Jeppesen J, Kjaergaard J, Wanscher M, Nielsen N, Friberg H, Bjerre M, et al. The inflammatory response after out-of-hospital cardiac arrest is not modified by targeted temperature management at 33 °C or 36 °C. Resuscitation. 2014;85(11):1480–7.  https://doi.org/10.1016/j.resuscitation.2014.08.007.CrossRefGoogle Scholar
  47. 47.
    Stammet P, Devaux Y, Azuaje F, Werer C, Lorang C, Gilson G, et al. Assessment of procalcitonin to predict outcome in hypothermia-treated patients after cardiac arrest. Crit Care Res Pract. 2011;2011:631062.  https://doi.org/10.1155/2011/631062.Google Scholar
  48. 48.
    Fries M, Kunz D, Gressner AM, Rossaint R, Kuhlen R. Procalcitonin serum levels after out-of-hospital cardiac arrest. Resuscitation. 2003;59(1):105–9.CrossRefGoogle Scholar
  49. 49.
    Adib-Conquy M, Monchi M, Goulenok C, Laurent I, Thuong M, Cavaillon JM, et al. Increased plasma levels of soluble triggering receptor expressed on myeloid cells 1 and procalcitonin after cardiac surgery and cardiac arrest without infection. Shock. 2007;28(4):406–10.  https://doi.org/10.1097/shk.0b013e3180488154.CrossRefGoogle Scholar
  50. 50.
    Fries M, Stoppe C, Brücken D, Rossaint R, Kuhlen R. Influence of mild therapeutic hypothermia on the inflammatory response after successful resuscitation from cardiac arrest. J Crit Care. 2009;24(3):453–7.  https://doi.org/10.1016/j.jcrc.2008.10.012.CrossRefGoogle Scholar
  51. 51.
    Hayashida H, Kaneko T, Kasaoka S, Oshima C, Miyauchi T, Fujita M, et al. Comparison of the predictability of neurological outcome by serum procalcitonin and glial fibrillary acidic protein in postcardiac-arrest patients. Neurocrit Care. 2010;12(2):252–7.  https://doi.org/10.1007/s12028-009-9318-5.CrossRefGoogle Scholar
  52. 52.
    Schuetz P, Affolter B, Hunziker S, Winterhalder C, Fischer M, Balestra GM, et al. Serum procalcitonin, C-reactive protein and white blood cell levels following hypothermia after cardiac arrest: a retrospective cohort study. Eur J Clin Investig. 2010a;40(4):376–81.  https://doi.org/10.1111/j.1365-2362.2010.02259.x.CrossRefGoogle Scholar
  53. 53.
    Annborn M, Dankiewicz J, Erlinge D, Hertel S, Rundgren M, Smith JG, et al. Procalcitonin after cardiac arrest - an indicator of severity of illness, ischemia-reperfusion injury and outcome. Resuscitation. 2013;84(6):782–7.  https://doi.org/10.1016/j.resuscitation.2013.01.004.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Raj Sahulee
    • 1
    Email author
  • Jaclyn McKinstry
    • 1
  • Sujata B. Chakravarti
    • 1
  1. 1.Department of Pediatrics, Division of CardiologyNew York University School of MedicineNew YorkUSA

Personalised recommendations